The University of Tennessee Research Foundation (UTRF) is announcing a call for submissions for the fifth annual maturation funding program. Proposals are due by Nov. 18, 2011. The program helps UT researchers further develop technologies that have potential for commercial success. Up to $15,000 (direct costs) will be awarded to the highest ranking proposals. Rules (read more)
UTRF News
RxBio Funded To Proceed With Developing A Radiation Countermeasure
The development of five new drugs to treat injuries associated with acute radiation syndrome will move forward under contracts awarded by the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA). Acute radiation syndrome is caused by exposure to high doses of damaging (ionizing) radiation. ARS includes injuries to multiple (read more)
Group A Streptococcus Vaccine on Path for Commercialization with Clinical Testing Agreement
An international collaboration between Vaxent, a Memphis-based early stage vaccine development company in the Memphis Bioworks Foundation Incubator, and The Pan-Provincial Vaccine Enterprise Inc. (PREVENT), a Centre of Excellence for Commercialization and Research (CECR) in Saskatchewan, has put a vaccine for group A streptococcus (Strep-A) back on the path for potential commercialization. Under the terms (read more)